TY  - JOUR
AU  - Gaito, S.
AU  - Hwang, E. J.
AU  - France, A.
AU  - Aznar, M. C.
AU  - Burnet, N.
AU  - Crellin, A.
AU  - Holtzman, A. L.
AU  - Indelicato, D. J.
AU  - Timmerman, B.
AU  - Whitfield, G. A.
AU  - Smith, E.
TI  - Outcomes of Patients Treated in the UK Proton Overseas Programme: Central Nervous System Group.
JO  - Clinical oncology
VL  - 35
IS  - 5
SN  - 0936-6555
CY  - [Erscheinungsort nicht ermittelbar]
PB  - Saunders
M1  - DKFZ-2023-00376
SP  - 283-291
PY  - 2023
N1  - 2023 May;35(5):283-291
AB  - In 2008, the UK National Health Service started the Proton Overseas Programme (POP), to provide access for proton beam therapy (PBT) abroad for selected tumour diagnoses while two national centres were being planned. The clinical outcomes for the patient group treated for central nervous system (CNS), base of skull, spinal and paraspinal malignancies are reported here.Since the start of the POP, an agreement between the National Health Service and UK referring centres ensured outcomes data collection, including overall survival, local tumour control and late toxicity data. Clinical and treatment-related data were extracted from this national patient database. Grade ≥3 late toxicities were reported following Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 definition, occurring later than 90 days since the completion of treatment.Between 2008 and September 2020, 830 patients were treated within the POP for the above listed malignancies. Overall survival data were available for 815 patients and local control data for 726 patients. Toxicity analysis was carried out on 702 patients, with patients excluded due to short follow-up (<90 days) and/or inadequate toxicity data available. After a median follow-up of 3.34 years (0.06-11.58), the overall survival was 91.2
KW  - Brain (Other)
KW  - late toxicities (Other)
KW  - paediatric (Other)
KW  - proton beam therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36804292
DO  - DOI:10.1016/j.clon.2023.01.024
UR  - https://inrepo02.dkfz.de/record/271244
ER  -